HUE031823T2 - Eljárás csökkentett oldott oxigénszintû humán albumin elõállítására - Google Patents
Eljárás csökkentett oldott oxigénszintû humán albumin elõállítására Download PDFInfo
- Publication number
- HUE031823T2 HUE031823T2 HUE15382164A HUE15382164A HUE031823T2 HU E031823 T2 HUE031823 T2 HU E031823T2 HU E15382164 A HUE15382164 A HU E15382164A HU E15382164 A HUE15382164 A HU E15382164A HU E031823 T2 HUE031823 T2 HU E031823T2
- Authority
- HU
- Hungary
- Prior art keywords
- albumin
- solution
- ahol ahol
- stage
- oxygen
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 81
- 239000001301 oxygen Substances 0.000 title claims description 48
- 229910052760 oxygen Inorganic materials 0.000 title claims description 48
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title claims description 45
- 108091006905 Human Serum Albumin Proteins 0.000 title claims description 19
- 102000008100 Human Serum Albumin Human genes 0.000 title claims description 19
- 238000002360 preparation method Methods 0.000 title description 7
- 230000002829 reductive effect Effects 0.000 title description 7
- 102000009027 Albumins Human genes 0.000 claims description 161
- 108010088751 Albumins Proteins 0.000 claims description 161
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 63
- 239000011261 inert gas Substances 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 15
- 230000005587 bubbling Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 239000012298 atmosphere Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 230000009467 reduction Effects 0.000 claims description 7
- 239000007789 gas Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 229910001873 dinitrogen Inorganic materials 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229910052744 lithium Inorganic materials 0.000 claims 1
- 238000011946 reduction process Methods 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 229940050528 albumin Drugs 0.000 description 157
- 239000000243 solution Substances 0.000 description 91
- 238000009928 pasteurization Methods 0.000 description 33
- 229910052757 nitrogen Inorganic materials 0.000 description 29
- 238000004381 surface treatment Methods 0.000 description 20
- 239000000047 product Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 239000001307 helium Substances 0.000 description 14
- 229910052734 helium Inorganic materials 0.000 description 14
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 14
- 230000001590 oxidative effect Effects 0.000 description 13
- 210000002381 plasma Anatomy 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- 239000002033 PVDF binder Substances 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 238000011146 sterile filtration Methods 0.000 description 5
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012859 sterile filling Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- -1 thiol compound Chemical class 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 108010004546 mercaptoalbumin Proteins 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000008174 sterile solution Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 229920005556 chlorobutyl Polymers 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005184 irreversible process Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004792 oxidative damage Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000001581 pretranslational effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- 208000010334 End Stage Liver Disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- DZTHIGRZJZPRDV-LBPRGKRZSA-N N-acetyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H](NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-LBPRGKRZSA-N 0.000 description 1
- DZTHIGRZJZPRDV-UHFFFAOYSA-N Nalpha-Acetyltryptophan Natural products C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241001639412 Verres Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000011444 chronic liver failure Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940116191 n-acetyltryptophan Drugs 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960005480 sodium caprylate Drugs 0.000 description 1
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical compound [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Claims (3)
- ILJÄli Ç^mmmn OLDOTT ÛXiOÉbf|«fö M«Ä 1»WIÍ I|JàLÜÎÀSÂR& Izabaitaimt % Pl'árás humán aibumte oldatának oldâlli^ms asaj j^femewf, he|y 11: 0Prás tartalma« az álbumímoldátbán 0^0l1 oxigén csfkkenjlsirtek: műveletét, ahol az «|én-szintst 0,5 pprn koncentfáaóra vagy m alá csökkentjük, J* Az 1 igénypont szerinti eljárás, azzatjatbmozve, hogy az alhumzrAdatban mm mm iÄ^iÖliÄiä müveimet az albumaidat meri gázzal iv Az 1, Igénypont szerinti eljárás, azzal jeüemezve, hogy az oldatban Azé giútt ex|lri: csökkentésének műveletét ínért gáznak az alhumin-oídat belsejébe történő buborékoitatásávaívégazzuk. #, Az 1-3. igénypontok bármelyike szpnnti eijirii, ***** m albumin plazmáé mfembfriáos vágata
- 5. Az 1-4. igénypontok bármelyiké szerinti eljárás, azzal jellemezve, hegy az alhurninzédat altximinkoMicontráoiéja körülbelül 4-25 vegyes%~os.. β, A 2~5. igénypontok bármelyike szerinti eljárás, azzal jellemazves hogy az Wa Az T-i. Igénypontok bármelyike szerinti ellátás, azzal jellemezve, hogy az ilburnin-oigálbah lévé oldott oxigén csökkentésének művelete az albumin-oldat egy pasztörózéss müve le le előtt történik. I, Az 1-7, i§ènypoo!ûk bármelyike szerinti eljárás, azzal Jellemezve, 1^117 &*· Ilki oldott oxigén csökkentésének műveleti m ektaiegy pásztőriziif művelete elán történik, ti Az 1-8. igénypontok bármelyike szedrét épris, azzet pliimettm  gfÖnmip-etdatban lévő oldott oxigén csökkentésének művelete útin az aibumirvoldstot inert gáz. atmoszféra alatt tartjuk ft, A 9. igénypont szerinti eljárás, azzal jellemezve, begy az inert gáz atmoszféra nitrogéngáz- vagy héitumgáz-atmoszféra. II, Az 1-10. igénypontok bármelyike szerinti eljárás, azzal jellemezve, begy az síbumin-oldatot oxigén szamára Impermeábills anyagból készük tárolóeszközbe csomagoljuk és/vagy Ilyen tárolóeszközben tároljuk, 12, A 11. igénypont szerinti eljárás, azzal jellemezve, bogy az oxigén számára impermeábilis anyag üveg.
- 13, Készítmény, amely tartalmaz az 1-12. igénypontok bármelyike szednll eljárással előállított humán albumint. azzal jellemezve, bogy oldott oxigén koncentrációja legfeljebb 0,5 ppm. 14, .A 13. igénypont szerinti, albumínt tartalmazó készítmény gyógyszerként történő alkalmazásra.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430824A ES2524516B1 (es) | 2014-05-29 | 2014-05-29 | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE031823T2 true HUE031823T2 (hu) | 2017-08-28 |
Family
ID=52003454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15382164A HUE031823T2 (hu) | 2014-05-29 | 2015-04-01 | Eljárás csökkentett oldott oxigénszintû humán albumin elõállítására |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US10350274B2 (hu) |
| EP (1) | EP2952203B9 (hu) |
| JP (3) | JP2015224251A (hu) |
| KR (1) | KR101960729B1 (hu) |
| CN (1) | CN105315362B (hu) |
| AR (1) | AR100618A1 (hu) |
| AU (1) | AU2015202413B2 (hu) |
| BR (1) | BR102015012091A8 (hu) |
| CA (1) | CA2890642C (hu) |
| CL (1) | CL2015001446A1 (hu) |
| ES (2) | ES2524516B1 (hu) |
| HU (1) | HUE031823T2 (hu) |
| IL (1) | IL238898B (hu) |
| MX (1) | MX362869B (hu) |
| MY (1) | MY171771A (hu) |
| NZ (1) | NZ708537A (hu) |
| PL (1) | PL2952203T3 (hu) |
| PT (1) | PT2952203T (hu) |
| RU (1) | RU2657578C2 (hu) |
| SG (1) | SG10201504137PA (hu) |
| TW (1) | TWI607018B (hu) |
| ZA (1) | ZA201503539B (hu) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
| WO2017189919A2 (en) | 2016-04-28 | 2017-11-02 | Alkahest, Inc. | Blood plasma and plasma fractions as therapy for tumor growth and progression |
| KR20220107322A (ko) | 2016-08-18 | 2022-08-02 | 알카헤스트 인코포레이티드 | 노화-관련된 인지 장애 치료제로서의 혈장 분획 |
| UA127828C2 (uk) | 2017-04-26 | 2024-01-17 | Алкахест, Інк. | Спосіб застосування фракції білків плазми крові для лікування когнітивних порушень |
| MA53182A (fr) | 2018-07-20 | 2021-05-26 | Alkahest Inc | Schéma posologique pour le traitement de déficiences cognitives et motrices avec du plasma sanguin et des produits à base de plasma sanguin |
| CN109627322A (zh) * | 2019-01-07 | 2019-04-16 | 中国科学院过程工程研究所 | 一种从Cohn组分Ⅴ上清中分离纯化人血清白蛋白的方法 |
| WO2024200553A1 (en) | 2023-03-29 | 2024-10-03 | Grifols Worldwide Operations Limited | COMPOSITIONS AND METHODS OF PREPARATION OF BLOOD PLASMA PRODUCTS WITH REDUCED LEVELS OF FceRIß AUTOANTIBODIES |
| CN118166053A (zh) * | 2024-03-15 | 2024-06-11 | 通化安睿特生物制药股份有限公司 | 一种制备低o-糖基化水平的重组人白蛋白的方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4094965A (en) * | 1977-04-01 | 1978-06-13 | New England Nuclear Corporation | Diagnostic agents containing albumin and method for making same |
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| JPH07126182A (ja) * | 1993-10-27 | 1995-05-16 | Green Cross Corp:The | 組換えヒト血清アルブミン製剤の滅菌方法 |
| SE9402119D0 (sv) * | 1994-06-16 | 1994-06-16 | Pharmacia Ab | Solution |
| US5766582A (en) * | 1994-10-11 | 1998-06-16 | Schering Corporation | Stable, aqueous alfa interferon solution formulations |
| EP1245217B1 (en) * | 2001-03-27 | 2009-10-28 | Nipro Corporation | Plastic container containing albumin solution |
| JP4254117B2 (ja) * | 2001-03-27 | 2009-04-15 | ニプロ株式会社 | アルブミン溶液収容プラスチック容器 |
| JP4225416B2 (ja) * | 2001-06-29 | 2009-02-18 | 旭化成ファーマ株式会社 | タンパク質製剤の安定性を改善する方法 |
| US7252799B2 (en) * | 2001-08-31 | 2007-08-07 | Clearant, Inc. | Methods for sterilizing preparations containing albumin |
| US7285379B2 (en) * | 2003-08-28 | 2007-10-23 | Nipro Corporation | Artificial oxygen carrier and production method thereof |
| PL1986612T3 (pl) * | 2006-02-07 | 2013-02-28 | Shire Human Genetic Therapies | Stabilizowana kompozycja glukocerebrozydazy |
| ES2294976B1 (es) * | 2007-11-12 | 2008-12-16 | Grifols, S.A. | "procedimiento de obtencion de albumina humana de alta eficacia para su uso en terapia de detoxificacion". |
| JP5990880B2 (ja) * | 2011-08-31 | 2016-09-14 | 東レ株式会社 | 有用タンパク質組成物およびその製造方法 |
| CN102816230B (zh) * | 2012-08-27 | 2014-02-12 | 同路生物制药股份有限公司 | 人血白蛋白的制备方法 |
| ES2524516B1 (es) * | 2014-05-29 | 2015-03-31 | Grifols Worldwide Operations Limited | Procedimiento de preparación de albúmina humana con nivel de oxígeno disuelto reducido |
-
2014
- 2014-05-29 ES ES201430824A patent/ES2524516B1/es not_active Expired - Fee Related
-
2015
- 2015-04-01 HU HUE15382164A patent/HUE031823T2/hu unknown
- 2015-04-01 EP EP15382164.0A patent/EP2952203B9/en active Active
- 2015-04-01 PL PL15382164T patent/PL2952203T3/pl unknown
- 2015-04-01 PT PT153821640T patent/PT2952203T/pt unknown
- 2015-04-01 ES ES15382164.0T patent/ES2601137T3/es active Active
- 2015-05-01 CA CA2890642A patent/CA2890642C/en active Active
- 2015-05-06 AU AU2015202413A patent/AU2015202413B2/en active Active
- 2015-05-15 MY MYPI2015701570A patent/MY171771A/en unknown
- 2015-05-18 RU RU2015118453A patent/RU2657578C2/ru active
- 2015-05-19 IL IL238898A patent/IL238898B/en active IP Right Grant
- 2015-05-20 ZA ZA2015/03539A patent/ZA201503539B/en unknown
- 2015-05-21 MX MX2015006407A patent/MX362869B/es active IP Right Grant
- 2015-05-22 CN CN201510264800.9A patent/CN105315362B/zh active Active
- 2015-05-26 TW TW104116876A patent/TWI607018B/zh not_active IP Right Cessation
- 2015-05-26 BR BR102015012091A patent/BR102015012091A8/pt not_active IP Right Cessation
- 2015-05-26 SG SG10201504137PA patent/SG10201504137PA/en unknown
- 2015-05-27 NZ NZ708537A patent/NZ708537A/en not_active IP Right Cessation
- 2015-05-27 AR ARP150101653A patent/AR100618A1/es active IP Right Grant
- 2015-05-28 CL CL2015001446A patent/CL2015001446A1/es unknown
- 2015-05-28 JP JP2015108569A patent/JP2015224251A/ja active Pending
- 2015-05-28 KR KR1020150074568A patent/KR101960729B1/ko active IP Right Grant
- 2015-05-28 US US14/724,649 patent/US10350274B2/en active Active
-
2018
- 2018-04-27 JP JP2018086673A patent/JP2018115210A/ja active Pending
-
2020
- 2020-04-20 JP JP2020074749A patent/JP2020111614A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE031823T2 (hu) | Eljárás csökkentett oldott oxigénszintû humán albumin elõállítására | |
| JP4878664B2 (ja) | 安定な液体インターフェロン処方物 | |
| EA025663B1 (ru) | Композиции этанерцепта, стабилизированные ионами металлов | |
| CN1330370C (zh) | 稳定的白蛋白制剂 | |
| Belew et al. | Purification of recombinant human serum albumin (rHSA) produced by genetically modified Pichia pastoris | |
| JPH0733800A (ja) | 精製単量体健康人血清アルブミン（ヒト） | |
| Scudder | STUDIES IN BLOOD PRESERVATION*: THE STABILITY OF PLASMA PROTEINS | |
| US20030080056A1 (en) | Extraction of biological components from body fluids | |
| DE60304603T2 (de) | Plasma-albumin fraktion mit vermindertem prekallikrein | |
| US20220411467A1 (en) | Protein bioprocess | |
| Arvinte et al. | The formulation of biological molecules | |
| DE60304040T2 (de) | Methode zur identifizierung und eliminierung von t-zell epitopen | |
| RU2391354C1 (ru) | Комплекс биологически активного рекомбинантного белка с полисиаловой кислотой | |
| WO2002072135A1 (fr) | Preparations d'interferon alpha liquide pour injection et procede de stabilisation de celles-ci | |
| Akbarzadehlaleh et al. | An efficient non-chromatographic method to separate human serum albumin from cryo-poor plasma | |
| Krijnen et al. | Preparation and properties of a stable human plasma protein solution | |
| Idar et al. | Purification of IgY Anti-SARS-CoV-2-Chicken Nucleocapsid and Elimination of Its Low-temperature Storage-induced Aggregates | |
| US6586394B1 (en) | Tissue-derived tumor growth inhibitor | |
| Combridge et al. | Plasma protein fraction: the disappearance of kinin from the solution on storage | |
| Lang et al. | Chemical characterization of human urine albumin in proteinuria | |
| CN1700928A (zh) | 用于治疗重症患者的方法和药剂 | |
| DE3537870A1 (de) | Mit penicillamin behandelte injizierbare loesungen aus menschlichem vollblut und daraus gewonnene blutfraktionen | |
| JPS61194027A (ja) | アルブミン製剤の製造法 | |
| JPS6254776B2 (hu) |